MMV welcomes proposals in the following three areas

1. Compounds addressing the key priorities of the malaria eradication agenda

Novel families of molecules in the hit-to-lead or lead optimization stages are sought without G6PD deficiency liabilities that either:

• Kill or reactivate hypnozoites for use as part of a P. vivax radical cure; or
• Have activity against sexual stage V gametocytes and evidence of transmission blocking in SMFA.

2. Compounds with activity against asexual liver and/or blood stages

Novel chemical series with EC50<500nM and which have one or more of the following key features:

• A known, novel mechanism of action;
• An inability to select resistant mutants in vitro;
• Activity at more than one life-cycle stage;
• A long half-life (ideally >4h in rodents) and confirmed in vivo efficacy.
• For advanced series, we are seeking novel compounds with, ideally, a predicted human half-life >100h and a predicted oral single human dose <500mg or an i.m. dose that can be administered in <1mL and sufficient for up to 3 months’ protection in humans.

3. Novel approaches for screening

• To help identify new phenotypic and/ or target based hits, as well as confirm activity of MMV compounds on all human malaria asexual blood stages, new screening proposals are sought .